U.S. Tumor Ablation Market (By Technology; By Treatment: Surgical, Laparoscopic; By Application: Liver Cancer, Kidney Cancer) - Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2024-2033

The U.S. tumor ablation market was estimated at USD 414.72 million in 2023 and it is expected to surpass around USD 1,488.28 million by 2033, poised to grow at a CAGR of 13.63% from 2024 to 2033.

U.S. Tumor Ablation Market Size 2024 to 2033

Key Pointers

  • By Technology, the radiofrequency tumor ablation generated the maximum market share of 33% in 2023.
  • By Technology, the microwave ablation technology is expected to grow at the notable CAGR during the forecast period.
  • By Treatment, the percutaneous ablation segment captured the maximum market share of 57% in 2023.
  • By Application, the liver cancer segment had the largest market share of 22% in 2023.
  • By Application, the lung cancer segment is expected to grow at the highest growth rate from 2024 to 2033.

U.S. Tumor Ablation Market Overview

The U.S. tumor ablation market stands as a vital segment within the broader landscape of cancer treatment technologies. With a growing emphasis on minimally invasive procedures and advancements in medical technology, tumor ablation has emerged as a promising alternative for patients seeking effective treatment options.

U.S. Tumor Ablation Market Growth Factors

The growth of the U.S. tumor ablation market is driven by an advancement in medical technology have significantly improved the efficacy and precision of tumor ablation procedures, making them increasingly attractive to patients and healthcare providers. Additionally, the rising incidence of cancer in the U.S. population has created a growing demand for effective and less invasive treatment options, further fueling market growth. Moreover, favorable reimbursement policies for tumor ablation procedures have reduced financial barriers, facilitating greater accessibility and adoption of these technologies. Furthermore, collaborative initiatives among industry players, healthcare providers, and research institutions have accelerated innovation and market penetration, contributing to sustained growth.

U.S. Tumor Ablation Market Trends:

  • Minimally Invasive Procedures: Growing preference for minimally invasive treatment options is boosting the adoption of tumor ablation techniques among patients seeking reduced recovery times and fewer complications.
  • Technological Advancements: Rapid advancements in medical technology, including image-guided ablation systems and real-time monitoring capabilities, are enhancing the precision and efficacy of tumor ablation procedures, expanding their applicability across various cancer types.
  • Diversification of Indications: Tumor ablation techniques are expanding beyond traditional indications, encompassing a broader spectrum of cancer types and anatomical locations, thus widening the scope of treatment options available to patients.
  • Increasing Incidence of Cancer: The rising prevalence of cancer in the U.S. population is driving the demand for innovative treatment modalities such as tumor ablation, as patients seek effective and less invasive therapeutic interventions.
  • Demand for Personalized Medicine: There is a growing emphasis on personalized medicine and precision oncology, which is driving the development of targeted tumor ablation approaches tailored to individual patient characteristics and tumor biology.
  • Integration of Multimodal Therapies: Tumor ablation is increasingly being integrated into multimodal treatment regimens, including combination therapies with chemotherapy, immunotherapy, and radiation therapy, to optimize treatment outcomes and improve patient survival rates.

U.S. Tumor Ablation Market Challenges:

  • High Initial Investment Costs: The upfront costs associated with acquiring tumor ablation equipment and establishing infrastructure for these procedures can be substantial. This high initial investment presents a barrier to entry for healthcare facilities, particularly smaller practices or those with limited financial resources.
  • Technical Expertise Requirement: Performing tumor ablation procedures requires specialized technical expertise and training. The shortage of skilled healthcare professionals proficient in ablation techniques can limit the widespread adoption of these procedures and pose challenges for healthcare facilities aiming to offer them as part of their service offerings.
  • Risk of Complications and Adverse Events: While tumor ablation is generally considered safe, there is a risk of complications and adverse events, including damage to surrounding tissues or organs, infection, and incomplete tumor ablation. Mitigating these risks requires careful patient selection, procedural planning, and ongoing monitoring, adding complexity to the treatment process.
  • Competition from Alternative Therapies: Tumor ablation faces competition from alternative cancer treatment modalities such as surgery, chemotherapy, radiation therapy, and emerging technologies like immunotherapy. Healthcare providers must weigh the benefits and limitations of each approach, making informed decisions based on patient-specific factors and tumor characteristics.

Technology Insights

Radiofrequency tumor ablation dominated the revenue share in 2023, accounting for 33%. This dominance stems from its efficiency and specificity in ablating solid tumors in organs like the liver and kidney. Moreover, radiofrequency ablation offers the capability to treat multiple tumors simultaneously, enhancing procedural efficiency through the utilization of various electrodes positioned at different sites. These factors are expected to drive increased adoption of advanced tumor ablation solutions.

Microwave ablation technology is anticipated to experience the highest compound annual growth rate (CAGR) during the forecast period. Microwave ablation utilizes electromagnetic waves to destroy tumors, with the device operating at a frequency of at least 900 MHz. It offers several advantages over alternative techniques, particularly in terms of its effectiveness in eliminating tumor cells. Benefits of microwave ablation technology include the ability to ablate larger tumor volumes, reduced patient discomfort, consistent high temperature, shorter ablation duration, and optimal heating of cystic masses. These advantages are poised to stimulate growth within the segment.

Treatment Insights

The percutaneous ablation segment held the largest revenue share of 57% in 2023. Percutaneous tumor ablation, a minimally invasive medical procedure, obviates the need for open surgery by targeting tumors from outside the body through the skin. This approach employs various energy sources, such as heat or cold, to eradicate or reduce tumor tissue. Percutaneous ablation frequently utilizes image guidance methods such as ultrasound, CT scans, or MRI to precisely target the tumor. Thermal ablation of localized solid tumors is currently achievable through a range of percutaneous image-guided techniques.

The laparoscopic ablation segment is expected to witness the swiftest compound annual growth rate (CAGR) over the forecast period. Laparoscopic ablation is a minimally invasive surgical technique that employs heat or cold to eliminate tumors. In comparison to conventional open surgery, laparoscopic ablation involves making small incisions through which specialized instruments and a camera (laparoscope) are inserted to access and treat the tumor. This approach offers advantages such as reduced postoperative discomfort, shorter hospital stays, and faster recovery times. It provides benefits like decreased pain, shorter hospitalizations, and quicker recovery periods when compared to traditional surgical procedures.

Application Insights

The liver cancer segment held the largest market share in 2023, accounting for 22%. Liver cancer is recognized as one of the most prevalent forms of cancer. According to the American Cancer Society, approximately 41,210 new cases of liver cancer were diagnosed in the U.S. in 2023, with 27,980 cases in men and 13,230 cases in women. The projected number of deaths from liver cancer is 29,380, with 19,000 in men and 10,380 in women. Minimally invasive procedures, such as those involving the use of needles or probes, are gaining traction as they do not necessitate hospital stays, leading to increased adoption of these techniques.

The lung cancer segment is expected to exhibit the highest growth rate during the forecast period. This growth can be attributed to the rising incidence of lung cancer, primarily due to the increasing prevalence of smoking.

U.S. Tumor Ablation Market Key Companies

  • Medtronic plc.
  • Boston Scientific Corporation
  • Johnson & Johnson Service Inc. (Ethicon, Inc.)
  • AngioDynamics
  • Bioventus Inc. (Misonix Inc.)
  • Chongqing Haifu Medical Technology Co., Ltd
  • Mermaid Medical
  • HealthTronics, Inc.
  • H.S. Hospital Service S.p.A

Recent Developments

  • In August 2023, Bioventus Inc. (formerly Misonix Inc.) obtained clearance from the U.S. FDA for its neXus SonaStar Elite handpiece, enabling its use in a range of procedures, including the removal of malignant and benign spinal and brain tumors.
  • In March 2023, AngioDynamics established a new partnership with Minimax Medical for the global distribution of its product portfolio.

U.S. Tumor Ablation Market Segmentations:

By Technology

  • Radiofrequency ablation
  • Microwave ablation
  • Cryoablation
  • Irreversible electroporation ablation
  • HIFU
  • Other ablation technologies

By Treatment

  • Surgical ablation
  • Laparoscopic ablation
  • Percutaneous ablation

By Application

  • Kidney cancer
  • Liver cancer
  • Breast cancer
  • Lung cancer
  • Prostate cancer
  • Other cancer

Frequently Asked Questions

The U.S. tumor ablation market size was reached at USD 414.72 million in 2023 and it is projected to hit around USD 1,488.28 million by 2033.

The U.S. tumor ablation market is growing at a compound annual growth rate (CAGR) of 13.63% from 2024 to 2033.

Key factors that are driving the U.S. tumor ablation market growth include rising need for solutions to reduce healthcare costs, increasing focus on patient-centric care, and strong government support.

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Technology Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on U.S. Tumor Ablation Market 

5.1. COVID-19 Landscape: U.S. Tumor Ablation Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape List of Suppliers List of Buyers

Chapter 8. U.S. Tumor Ablation Market, By Technology

8.1. U.S. Tumor Ablation Market, by Technology, 2024-2033

8.1.1 Radiofrequency ablation Market Revenue and Forecast (2021-2033)

8.1.2. Microwave ablation Market Revenue and Forecast (2021-2033)

8.1.3. Cryoablation Market Revenue and Forecast (2021-2033)

8.1.4. Irreversible electroporation ablation Market Revenue and Forecast (2021-2033)

8.1.5. HIFU Market Revenue and Forecast (2021-2033)

8.1.6. Other ablation technologies Market Revenue and Forecast (2021-2033)

Chapter 9. U.S. Tumor Ablation Market, By Treatment

9.1. U.S. Tumor Ablation Market, by Treatment, 2024-2033

9.1.1. Surgical ablation Market Revenue and Forecast (2021-2033)

9.1.2. Laparoscopic ablation Market Revenue and Forecast (2021-2033)

9.1.3. Percutaneous ablation Market Revenue and Forecast (2021-2033)

Chapter 10. U.S. Tumor Ablation Market, By Application 

10.1. U.S. Tumor Ablation Market, by Application, 2024-2033

10.1.1. Kidney cancer Market Revenue and Forecast (2021-2033)

10.1.2. Liver cancer Market Revenue and Forecast (2021-2033)

10.1.3. Breast cancer Market Revenue and Forecast (2021-2033)

10.1.4. Lung cancer Market Revenue and Forecast (2021-2033)

10.1.5. Prostate cancer Market Revenue and Forecast (2021-2033)

10.1.6. Other cancer Market Revenue and Forecast (2021-2033)

Chapter 11. U.S. Tumor Ablation Market, Regional Estimates and Trend Forecast

11.1. U.S.

11.1.1. Market Revenue and Forecast, by Technology (2021-2033)

11.1.2. Market Revenue and Forecast, by Treatment (2021-2033)

11.1.3. Market Revenue and Forecast, by Application (2021-2033)

Chapter 12. Company Profiles

12.1. Medtronic plc.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Boston Scientific Corporation.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Johnson & Johnson Service Inc. (Ethicon, Inc.).

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. AngioDynamics.

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Bioventus Inc. (Misonix Inc.).

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. EDAP TMS

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Chongqing Haifu Medical Technology Co., Ltd.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Mermaid Medical

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. HealthTronics, Inc.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. H.S. Hospital Service S.p.A

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms

Proceed To Buy

USD 3800
USD 1900
USD 1200

Customization Offered

  • check-imgCross-segment Market Size and Analysis for Mentioned Segments
  • check-imgAdditional Company Profiles (Upto 5 With No Cost)
  • check-img Additional Countries (Apart From Mentioned Countries)
  • check-img Country/Region-specific Report
  • check-img Go To Market Strategy
  • check-imgRegion Specific Market Dynamics
  • check-imgRegion Level Market Share
  • check-img Import Export Analysis
  • check-imgProduction Analysis
  • check-imgOthers